Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer

Launched by RUIJIN HOSPITAL · Jun 15, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for advanced colorectal cancer, which is cancer that has spread and is no longer responding to standard therapies. The treatment involves taking immune cells called T cells from a patient’s own tumor, then modifying these cells in the lab to remove a protein called PD-1. Normally, tumors use PD-1 to "turn off" the immune cells and protect themselves, but by removing PD-1, these modified T cells can better recognize and attack the cancer. After the cells are grown and tested for safety, they are given back to the patient to help fight the cancer.

People who might be eligible for this study are adults between 18 and 70 years old with advanced colorectal cancer that cannot be treated with standard options. Participants must have at least one tumor that can be measured and be healthy enough for surgery or a biopsy to collect tumor tissue. The study is carefully designed to include patients with good overall health and without serious infections, immune problems, or other major medical issues. If you join, you can expect to undergo surgery or a biopsy to collect tumor cells, followed by receiving the specially modified T cells back into your body. The main goal is to see if this treatment is safe and to learn how well it works for advanced colorectal cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with advanced colorectal cancer confirmed by histology or cytology, who were not eligible to standard treatment at this stage.
• • Patients volunteered to receive surgery or biopsy to obtain tumor tissue for TILs preparation.
• • Aged ≥18 and ≤70 years old.
• • At least one tumor lesion that could be evaluated according to RECIST, version 1.1.
• • ECOG score was 0 or 1.
• • Adequate bone marrow and organ function.
• • The expected survival time of the enrolled patients was no less than 6 months.
• Exclusion Criteria:
• * Received chemotherapy, radiotherapy, biological therapy, endocrine therapy, immunotherapy, traditional Chinese medicine with anti-tumor indications and other anti-tumor treatments within 2 weeks before sampling, except the following:
• • 1. Nitrosourea or mitomycin C within 6 weeks before surgery;
• • 2. Oral fluorouracils and small molecule targeted drugs for 1 week before surgery.
• • Received other unmarketed investigational drug or treatment within 4 weeks before sampling;
• • Had undergone major organ surgery (excluding needle biopsy) within 4 weeks before sampling or had significant lesions Trauma, or the need for elective surgery during the trial;
• • Received systemic glucocorticoid (prednisone \>10mg/ day or equivalent dose) or other immunosuppressive therapy within 14 days before sampling; Treatment with topical, ocular, intra-articular, nasal, and inhaled glucocorticoids was excluded. Short-term prophylaxis with glucocorticoids (e.g., to prevent contrast allergy)
• • Use of immunomodulatory drugs, including but not limited to thymosin, interleukin-2, interferin, etc., within 14 days before sampling;
• • Administration of live attenuated vaccine within 4 weeks before sampling;
• • The toxicity of previous antineoplastic therapy has not recovered to CTCAE 5.0 grade ≤1 (except for alopecia and other researchers who judged that there was no safety risk);
• • Patients with symptomatic central nervous system or leptomeningeal metastases or other evidence of uncontrolled central nervous system or leptomeningeal metastases as judged by the investigator to be ineligible for enrollment;
• • Patients with active infection within 1 week before sampling and currently requiring systemic anti-infective treatment;
• • A history of immunodeficiency, including positive HIV antibody test;
• • Hepatitis B (HBsAg positive and/or hepatitis C (anti-HCV positive) and/or treponema pallidum antibody positive;
• • Patients with current interstitial lung disease;
• * Has a history of severe cardiovascular and cerebrovascular diseases, including but not limited to:
• • 1. severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmia requiring clinical intervention, degree II-III atrioventricular block, etc.
• • 2. Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other grade 3 or higher cardiovascular and cerebrovascular events occurred within 6 months before the first dose of dose.
• • 3. New York Heart Association (NYHA) functional class ≥II or left ventricular ejection fraction (LVEF) \<50%, or structural heart disease at high risk as judged by other investigators;
• • 4. clinically uncontrolled hypertension.
• • Patients with active or previous autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.), excluding patients with clinically stable autoimmune thyroid diseases and well-controlled type I diabetes;
• • Received immunotherapy with grade ≥ 3 irAE;
• • Clinically uncontrollable serous cavity effusion, which was judged by the investigator as not suitable for enrollment;
• • Known alcohol or drug dependence;
• • Persons with mental disorders or poor compliance;
• • Pregnant or lactating women;